{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":385,"description":"PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.\n\nGa-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":385,"seriousNumAffected":0,"seriousNumAtRisk":385,"title":"Ga-68 Labeled PSMA-11 PET"}],"frequencyThreshold":"1","timeFrame":"Patients were monitored for adverse events during and for 2 hours after radiotracer administration. Patients were also contacted by phone to assess for the development of delayed adverse events up to 24 hours after radiotracer administration."}